PATENT CLAIM ANALYSIS

Application Number: 16159545
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "136100"]

Abstract:
Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.

Claim (Index 11):
The single domain BCMA binding protein of  claim 2 , wherein r1 comprises SEQ ID NO: 76, 114, 115, 116 or 117.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 97.0
- Lexical Diversity: 1.39024
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15977968', '15476309', '14805193', '15501620', '15237889']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7509617754152664
- 35 USC 102 Novelty (BERT): 0.5646134352369563
- Combined Prediction Score: 0.7323269413974354
- Mean Citation Score: 425.49164400000006
- Max Citation Score: 469.59668
- Similarity Product: 312.7424640548682

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test